Bangham D R, Gaines Das R E, Schulster D
Mol Cell Endocrinol. 1985 Oct;42(3):269-82. doi: 10.1016/0303-7207(85)90058-9.
Two preparations of human growth hormone (hGH) were prepared as candidates for the International Standard for Human Growth Hormone for Bioassay and were studied by 22 laboratories in 10 countries in an international collaborative study. The 2 candidate preparations, freeze-dried in ampoules coded 80/505 and 80/521, were assayed against the International Standard for Growth Hormone, bovine, for Bioassay (ISbGH), by in vivo assays; against the International Reference Preparation of Growth Hormone, human, for Immunoassay (IRP hGH), by receptor-, immunoassays and other in vitro methods; and against each other by various methods. Both preparations contained the 2 recognized main growth hormone components (22 kDa and 20 kDa forms) and other components, but that in ampoules coded 80/505 had less deamidated hGH and contaminant hormones and pyrogen than that in ampoules coded 80/521. The estimates by in vivo bioassays, using immature hypophysectomized rats, of the potency of 80/505 in terms of the IS bGH were heterogeneous (1-6 IU/ampoule), probably because of the dissimilarity of the preparations of bovine and human GH. Estimates with receptor- and immunoassays of 80/505 against the IRP hGH were also heterogeneous (3-9 IU/ampoule). Nevertheless, the majority of estimates from all assays tended to be between 3 and 6 IU/ampoule. Although 80/521 and 80/505 differed in relatively minor respects, assays of one directly against the other gave relative potency estimates with in vivo assays which were significantly different from estimates with in vitro methods. With the agreement of the participants in the study, the WHO Expert Committee on Biological Standardization established the preparation in ampoules coded 80/505 as the First International Standard for Human Growth Hormone for Bioassay, with the defined potency of 4.4 IU/ampoule. This corresponds to an approximate 2.5 IU/mg of hGH extract and maintains reasonable continuity of the unit.
制备了两种人生长激素(hGH)制剂作为生物测定用人生长激素国际标准品的候选品,并在一项国际协作研究中由10个国家的22个实验室进行了研究。这两种候选制剂冻干于编号为80/505和80/521的安瓿中,通过体内试验,以牛生长激素生物测定国际标准品(ISbGH)为对照进行测定;通过受体免疫测定法和其他体外方法,以人生长激素免疫测定国际参考制品(IRP hGH)为对照进行测定;并通过各种方法相互对照测定。两种制剂均含有2种公认的主要生长激素成分(22 kDa和20 kDa形式)及其他成分,但编号为80/505安瓿中的制剂比编号为80/521安瓿中的制剂含有更少的脱酰胺hGH、污染激素和热原。使用未成熟去垂体大鼠进行的体内生物测定对80/505相对于IS bGH效力的估计值存在异质性(1 - 6 IU/安瓿),这可能是因为牛生长激素和人生长激素制剂存在差异。80/505相对于IRP hGH的受体免疫测定估计值也存在异质性(3 - 9 IU/安瓿)。然而,所有测定的大多数估计值倾向于在3至6 IU/安瓿之间。尽管80/521和80/505在相对较小的方面存在差异,但一种制剂直接与另一种制剂进行测定时,体内试验的相对效力估计值与体外方法的估计值显著不同。经研究参与者同意,世界卫生组织生物标准化专家委员会将编号为80/505安瓿中的制剂确立为生物测定用人生长激素第一国际标准品,规定效力为4.4 IU/安瓿。这相当于约2.5 IU/mg的hGH提取物,并保持了单位的合理连续性。